|
Dear Anne,
My understanding is that Iressa has been a major disappointment in the trial results for breast cancer, to the point where I wouldn't be surprised if they pulled it altogether. Iressa is a targetted therapy very similar to lapatinib as a small molecule tryrosine kinase inhibitor. All the buzz about lapatinib seems very positive and I would persue that option first.
Kindest Regards,
Al
|